Skip to content

WHWK WHWK Other income, net (Note 6)

Other income, net (Note 6) at other companies

CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$7K-164%
Pfizer logo
PfizerPFE
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Cash & equivalents$34.8M-84.7%
Total debt$833.0K-34.3%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation

See full
Market cap$226.49M+131%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Debt / equity0.0×
Current ratio11.4×-7.6×

Where this comes from

Reported directly by WHWK in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: WHWK’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about WHWK's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WHWK's other income, net (note 6)?
WHWK (WHWK) reported other income, net (note 6) of $1.33M in Q1 2026.
How has WHWK's other income, net (note 6) changed year-over-year?
WHWK's other income, net (note 6) decreased by 98.5% year-over-year, from $88.23M to $1.33M.
What is the long-term trend for WHWK's other income, net (note 6)?
Over 3 years (2021 to 2025), WHWK's other income, net (note 6) has grown at a 336.4% compound annual growth rate (CAGR), from $1.13M to $93.8M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.